StemCyte Selected as a Technology Fast 500 Award Winner

Global Cord Blood Therapeutics Company Receives Prestigious Revenue Growth Honor from Deloitte

StemCyte, Inc., one of the world's preeminent cord blood banks and biotherapies companies, was recognized for its dramatic revenue growth as a Technology Fast 500(TM) award winner for 2009. Technology Fast 500(TM) is an award sponsored by Deloitte that recognizes 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America based on percentage of fiscal year revenue growth over five years.

Read Complete Story >

StemCyte Welcomes McCarthy to its Board

On December 2, the StemCyte, Inc. Board welcomed Mr. James McCarthy as its newest Member. Mr. McCarthy is the President of Genesis Consulting Group, Inc., and brings extensive board expertise and knowledge of the Financial and Healthcare markets in the USA, as well as abroad with specific and relevant experience in India and the Middle East.

StemCyte Signs Historical Agreement with Apollo Hospitals and Cadila Pharmaceuticals

Mr. Ken Giacin, Chairman and CEO of StemCyte, signed an historical agreement with Apollo Hospitals and Cadila Pharmaceuticals, which had put up the initial capital for the formation of StemCyte India. As the largest hospital chain outside of the US and as one of the five largest hospital chains in the world, the partnership with Apollo is expected to accelerate the growth of both the private and public bank business in India. As one of India’s largest pharmaceutical companies, StemCyte’s partnership with Cadila Pharmaceuticals is expected to add additional capabilities and credibility to the company’s growing international reputation. In addition, both Cadila and Apollo have generously provided both temporary and permanent facilities to house the Company’s India operations. Mr. Giacin held StemCyte India’s first board meeting with the Managing Directors of Apollo Hospitals and Cadila Pharmaceuticals on July 1 and the second board meeting is scheduled for November of 2008.

StemCyte Wins National Marrow Donor Award

It was announced today that StemCyte has been named the winner of the 2008 National Marrow Donor Program (NMDP) Health Partner Award. Dr. Lawrence Petz will receive the award at the NMDP’s Annual meeting in November of this year.

Dr Jaing (Chung Gung Memorial Hospital – Taiwan) was also informed that his ground breaking clinical work in treating and curing Thalassemia will be presented in a Oral Presentation at the prestigious American Society of Hematology (ASH) meeting in December. StemCyte’s transplant units are currently used by Dr Jaing, and StemCyte has been cited as a collaborator in this and other studies.

StemCyte Chairman and CEO Holds First Board Meeting in India

Mr. Giacin held StemCyte India’s first board meeting with the Managing Directors of Apollo Hospitals and Cadila Pharmaceuticals on July 1, where he was elected Chairman of StemCyte India. Key employees were also identified and an operations sub-committee was formed.

Research Agreement Signed with Rutgers University and Dr. Wise Young

Rutgers University, New Jersey – StemCyte today signed a definitive research agreement today with Rutgers University and Dr. Wise Young of the KECK Center. A signing ceremony was held at the KECK Center where New Jersey Governor Corzine, Mr. Giacin and Professor Wise Young addressed the crowd with their insights on this momentous occasion.

StemCyte Signs Agreement with China Medical University Hospital and Academia Sinica

StemCyte today signed an agreement with Professors Lin, Shyu and Li for the evaluation and commercialization of the use of UCB for the treatment of chronic stroke.

StemCyte Awarded Prestigious Sibling Donor Demonstration Grant from the US Government

Today, the Sibling Donor Demonstration Grant established a mechanism to collect an UCB unit from a newborn whose sibling is ill. This grant is designed to specifically help a family who has a child that is ill and is a candidate for a cord blood transplant.

StemCyte Welcomes New Board Member

The Board of StemCyte, Inc. welcomed its newest member, Mr. Barry Ressler, who was appointed to the Board on June 5, 2008. Mr. Ressler is a seasoned and very successful businessman and entrepreneur who has extensive experience in successfully growing businesses and taking them through liquidity.

The Annual Cord Blood Transplantation Symposium, now in its 6th year, was held in Los Angeles CA and is recognized as the leading symposium in the world for this field and the most recent event was widely hailed as the best so far. The Company’s Chief Medical Officer and organizer of this event, Dr. Lawrence Petz, along with the 5 UCB transplant pioneers, was honored, with an award, from the patients that received the first UCB transplants, that were honored The occasion celebrated the 20th anniversary of the first cord blood transplant. The five cord blood pioneers honored were Hal Broxmeyer, Ph.D., Joanne Kurtzberg, M.D., Eliane Gluckman, M.D., Pablo Rubinstein, M.D., and John Wagner, M.D. Over 500 international and U.S. transplant professionals attended.

Chairman and CEO of StemCyte Signs Historical Agreement

Mr. Ken Giacin, Chairman and CEO of StemCyte, signed a historical agreement with Apollo Hospitals and Cadila Pharmaceuticals, which put up the initial capital for the formation of StemCyte India. As the largest hospital chain outside of the US and as one of the five largest hospital chains in the world, the partnership with Apollo is expected to accelerate the growth of both the private and public bank business in India. As one of India’s largest pharmaceutical companies, our partnership with Cadila pharmaceutical is expected to add additional credibility to the Company’s growing international reputation.

StemCyte Expands Support of World Renowned Spinal Cord Injury Researcher Through Agreement with Rutgers University

StemCyte, Rutgers Sign Research, Licensing Agreement for Novel Human Umbilical Cord Blood Treatment for Spinal Cord Injury Being Developed by Wise Young, M.D., Ph.D.

StemCyte Inc. and Rutgers, The State University of New Jersey, today announced at the Stem Cell Summit that they have entered into a research and licensing agreement for a spinal cord injury therapy being developed by Wise Young, M.D., Ph.D., that uses StemCyte’s proprietary human umbilical cord blood (UCB) stem cells in conjunction with lithium.

Read Complete Story >

StemCyte to Present Overview of Company and its Umbilical Cord Blood Stem Cell Therapies at 3rd Annual Stem Cell Summit

World-Renowned Spinal Cord Injury Researcher and StemCyte Collaborator Wise Young to Participate in Presentation by Company’s Chairman

StemCyte Inc. today announced that Kenneth J. Giacin, chairman and chief executive officer, will present an overview of the company and its marketed umbilical cord blood stem cell therapies today at the 3rd Annual Stem Cell Summit in New York City.

Read Complete Story >

StemCyte Presents Six Abstracts on the Applications of Plasma-Depleted Umbilical Cord Blood Stem Cell Products at BMT Tandem Meetings

The benefits of plasma-depleted cord blood stem cell products were the subjects of six abstracts presented this week by StemCyte, Inc. and collaborators at the Bone Marrow Transplant (BMT) Tandem Meetings in San Diego. Three of them were presented orally and one was selected to be the best pediatric abstract.

Read Complete Story >

Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award from the National Marrow Donor Program

Dr. Auayporn Nademanee of City of Hope leads study showing efficacy of novel therapy

The National Marrow Donor Program (NMDP) has selected an abstract written by Dr. Auayporn Nademanee, physician and professor in the Division of Hematology & Hematopoietic Cell Transplantation at City of Hope, and Dr. Robert Chow, Founder and Global Medical Director for StemCyte, as one of four best abstracts at its annual Council Meeting in Minneapolis, MN.

Read Complete Story >

StemCyte®, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles

StemCyte, Inc. has been named to Deloitte's prestigious Technology Fast 50 Program for Los Angeles, a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in the area by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2002-2006.

Read Complete Story >

StemCyte®, Inc. Releases its 500^th Cord Blood Stem Cell Shipment for Transplant

Read Complete Story >

StemCyte®, Inc. Receives Contract from Federal Government to Help Build National Cord Blood Inventory for United States

Read Complete Story >

October 24, 2006

Dr. Lawrence Petz, Chief Medical Officer at Stemcyte®, Inc., receives Tibor Greenwalt Memorial Award and Lectureship

The AABB announced that Lawrence D. Petz, MD, chief medical officer at StemCyte, Inc., received the Tibor Greenwalt Memorial Award and Lectureship for 2006. According to the AABB, "This award recognizes an individual who made major scientific or clinical contributions to hematology and transfusion medicine and succinctly communicated these advances." Dr. Petz received the award at the AABB annual meeting in Miami, FL, which ends today.

Read Complete Story >

May 4, 2006

Stemcyte®, Inc. surpasses 300th cord blood unit shipped for transplant

StemCyte, Inc., a privately held stem cell therapy and cord blood bank, with highly accredited processing and storage facilities in both the U.S. and Taiwan, recently shipped its 300th cord blood stem cell unit for transplant. This marks another milestone in the company's rapid growth as one of the world's leading providers of quality cord blood stem cell units. StemCyte has now provided cord blood units to over 95 transplant centers worldwide across 5 continents, with the number of units released for transplantation increasing rapidly. StemCyte's units have been used for the treatment of over 40 diseases, including leukemias, lymphomas, immune diseases and genetic disorders.

Read Complete Story >

May 1, 2006

Stemcyte®, Inc. receives accreditation from Foundation for the Accreditation of Cellular Therapy

StemCyte, Inc., a privately held stem cell therapy and cord blood bank, has received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) for its International Cord Blood Center in Arcadia, California.  This accreditation means that the StemCyte International Cord Blood Center is now among a handful of cord blood banks to receive accreditation from the American Association of Blood Banks (AABB), the National Marrow Donor Program (NMDP), the College of American Pathologists (CAP), and Foundation for the Accreditation of Cellular Therapy (FACT) for allogeneic donations. The StemCyte International Cord Blood Center is now the first and the only cord blood bank in the world accredited by FACT for autologous donations.

Read Complete Story >

StemCyte®, Inc. surpasses 250th cord blood stem cell transplant

StemCyte, Inc., a privately held stem cell therapy and cord blood bank, with highly accredited processing and storage facilities in both the U.S. and Taiwan, recently contributed its 250th cord blood stem cell unit for transplant.  This marks another milestone in the company's rapid growth as one of the world's leading providers of quality cord blood stem cell units. StemCyte has now provided cord blood units to over 80 transplant centers worldwide across 5 continents, with the number of units released for transplantation is rapidly increasing.

Read Complete Story >

January 12, 2006

New study confirms prior research showing efficacy of using umbilical cord blood to treat Thalassemia patients

StemCyte, Inc. and International Experts Gather To Review Latest Advances in Blood-borne Disease

Arcadia, CA (January 12, 2006)- StemCyte, Inc., a leading, global umbilical cord blood (UCB) stem cell transplantation and therapeutic products company, today announced that a new study has confirmed prior research suggesting that unrelated UCB transplants may be a promising and cost-effective approach for curative therapy of thalassemia.  Approximately 150,000 children worldwide are born each year with a serious form of thalassemia that could be cured by UCB transplants that StemCyte has helped to pioneer.

Read Complete Story >

July 27, 2005

StemCyte®, Inc. Surpasses 200th Cord Blood Stem Cell Transplant Leading Breakthrough Clinical Study for Thalassemia in Taiwan

ARCADIA, Calif., July 26 /PRNewswire/ -- StemCyte, Inc., a privately held stem cell therapy and cord blood bank, contributed its 200th cord blood unit

for transplant last month, marking another milestone in the company's growth as one of the world's leading providers of quality cord blood stem cell units.  StemCyte has now provided cord blood units to over 80 transplant centers worldwide across 5 continents, and the number of units released for transplantation is rapidly increasing.

Read Complete Story >

July 19, 2005

StemCyte, Inc., Completes Significant Round of Financing

StemCyte(R), Inc., a leading umbilical cord blood stem cell transplantation and therapeutic products company, today announced it has recently completed a significant round of financing from new investors within both the United States and abroad. StemCyte sold approximately $13.7MM of new securities.

Read Complete Story >

July 1, 2005

Cord Blood In The News

During the past 18 months, there has been a flurry of media activity related to cord blood stem cell banking and transplantation. Most importantly, the emerging acceptance of transplant physicians to use cord blood stem cell transplants to address the lion share of the major unmet medical need, adult patients, is by far the most exciting development. 

Read Complete Story >